Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06497504 · ClinicalTrials.gov registry record · Phase 2

Study of Bepirovirsen in Participants Living With Human Immunodeficiency Virus and Chronic Hepatitis B Virus Infection (B-Focus)

A Phase 2 study of Hepatitis B, sponsored by GlaxoSmithKline.

Active
Registry status
Phase 2
Development phase
157
Enrollment target
20
Study locations

NCT06497504 is a Phase 2 study of Hepatitis B that is active but no longer recruiting, run by GlaxoSmithKline. The registered enrollment target is 157 participants, below the 1,624-participant average among 32 other Hepatitis B trials with a reported enrollment target (90% lower). The trial reports 20 study locations across 7 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06497504, a Phase 2 study of Hepatitis B, is active but no longer recruiting, sponsored by GlaxoSmithKline.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
157 participants
Enrollment target
20
Study locations

Study Summary

This study will evaluate the efficacy and safety of bepirovirsen compared to placebo in participants with human immunodeficiency virus (HIV)/hepatitis B virus (HBV) co-infection.

Conditions Studied

Hepatitis B

Interventions

  • DRUG Placebo
  • DRUG Bepirovirsen

Study Locations (20)

Other

  • GSK Investigational Site - Almagro
  • GSK Investigational Site - Buenos Aires
  • GSK Investigational Site - Buenos Aires
  • GSK Investigational Site - Buenos Aires
  • GSK Investigational Site - La Plata
  • GSK Investigational Site - Rosario
  • GSK Investigational Site - Aracaju
  • GSK Investigational Site - Campinas
  • GSK Investigational Site - Curitiba
  • GSK Investigational Site - Manaus
  • GSK Investigational Site - Salvador
  • GSK Investigational Site - São Paulo

California

  • GSK Investigational Site - Bakersfield
  • GSK Investigational Site - San Francisco

Florida

  • GSK Investigational Site - Orlando
  • GSK Investigational Site - West Palm Beach

Maryland

  • GSK Investigational Site - Baltimore

Minnesota

  • GSK Investigational Site - Minneapolis

New Jersey

  • GSK Investigational Site - Hillsborough

Ontario

  • GSK Investigational Site - Ottawa

Trial Details

FieldValue
Enrollment Target 157 participants
Start Date 2024-09-17
Est. Completion 2027-04-22
Phase Phase 2

Sponsor

GlaxoSmithKline

1,345 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06497504

The ClinicalTrials.gov registry entry for NCT06497504 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 157 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,624-participant average among 32 other Hepatitis B trials with a reported enrollment target (90% lower). The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Hepatitis B appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT06497504 reports 20 study locations spanning 7 distinct geographic areas - top geographies include Other, California, Florida.

Frequently Asked Questions

What is clinical trial NCT06497504 about?

NCT06497504 is a clinical study titled "Study of Bepirovirsen in Participants Living With Human Immunodeficiency Virus and Chronic Hepatitis B Virus Infection (B-Focus)". This study will evaluate the efficacy and safety of bepirovirsen compared to placebo in participants with human immunodeficiency virus (HIV)/hepatitis B virus (HBV) co-infection.

What is the current status of trial NCT06497504?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 157 participants. The study started on 2024-09-17. Estimated completion is 2027-04-22.

What conditions does trial NCT06497504 study?

This clinical trial studies the following conditions: Hepatitis B.

What interventions are being tested in trial NCT06497504?

The interventions under investigation include: Placebo (DRUG), Bepirovirsen (DRUG).

Who is sponsoring clinical trial NCT06497504?

This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06497504 being conducted?

This trial has 20 study locations across California, Florida, Maryland, Minnesota, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Hepatitis B

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Hepatitis B

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.